Citigroup
NRIX icon

Citigroup’s Nurix Therapeutics NRIX Stock Holding History

Citigroup’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.28M Buy
391,425
+2,041
+0.5% +$50.9K ﹤0.01% 1682
2026
Q2 		$9.45M Sell
389,384
-88,026
-18% -$1.5M ﹤0.01% 1664
2026
Q1 		$7.4M Buy
477,410
+306,308
+179% +$5.08M ﹤0.01% 1660
2025
Q4 		$3.25M Buy
171,102
+163,735
+2,223% +$2.35M ﹤0.01% 2325
2025
Q3 		$68.1K Sell
7,367
-36,360
-83% -$378K ﹤0.01% 4390
2025
Q2 		$498K Sell
43,727
-96,739
-69% -$1.05M ﹤0.01% 3630
2025
Q1 		$1.67M Buy
140,466
+33,116
+31% +$554K ﹤0.01% 2865
2024
Q4 		$2.02M Buy
107,350
+57,757
+116% +$1.32M ﹤0.01% 2809
2024
Q3 		$1.11M Buy
49,593
+22,171
+81% +$502K ﹤0.01% 3183
2024
Q2 		$572K Sell
27,422
-157,358
-85% -$2.45M ﹤0.01% 3305
2024
Q1 		$2.72M Buy
184,780
+169,635
+1,120% +$1.82M ﹤0.01% 2180
2023
Q4 		$156K Sell
15,145
-27,055
-64% -$185K ﹤0.01% 4030
2023
Q3 		$332K Sell
42,200
-4,760
-10% -$43.5K ﹤0.01% 3357
2023
Q2 		$469K Sell
46,960
-66,144
-58% -$675K ﹤0.01% 3421
2023
Q1 		$1M Buy
113,104
+39,508
+54% +$412K ﹤0.01% 2555
2022
Q4 		$808K Sell
73,596
-46,922
-39% -$566K ﹤0.01% 2813
2022
Q3 		$1.57M Buy
120,518
+45,253
+60% +$716K ﹤0.01% 2340
2022
Q2 		$954K Buy
75,265
+50,085
+199% +$568K ﹤0.01% 2701
2022
Q1 		$353K Sell
25,180
-51,431
-67% -$913K ﹤0.01% 3735
2021
Q4 		$2.22M Sell
76,611
-44,041
-37% -$1.34M ﹤0.01% 2546
2021
Q3 		$3.62M Sell
120,652
-1,859
-2% -$57.4K ﹤0.01% 2032
2021
Q2 		$3.25M Buy
122,511
+37,755
+45% +$1.11M ﹤0.01% 2275
2021
Q1 		$2.64M Buy
84,756
+81,242
+2,312% +$3.07M ﹤0.01% 2300
2020
Q4 		$116K Buy
3,514
+2,981
+559% +$98.8K ﹤0.01% 5422
2020
Q3 		$19K Buy
+533
New +$13.4K ﹤0.01% 6240

Other funds holding NRIX

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
WestHill Financial Advisors
WestHill Financial Advisors San Rafael, California $597M AUM 13.09% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Penn Capital Management
Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
AlphaCentric Advisors
AlphaCentric Advisors San Juan, Puerto Rico $113M AUM 27.37% 1-Year Est. Return

Citigroup's NRIX Position: Q3 2026 in Review

Citigroup increased its Nurix Therapeutics (NRIX) stake by 0.52% in Q3 2026, buying an estimated $50.9K and bringing the position to 391,425 shares worth $9.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1682.

Citigroup first reported a position in NRIX in Q3 2020 and has held it in 25 quarters since. The position peaked at $9.45M in Q2 2026. 51 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Citigroup held 391,425 shares of Nurix Therapeutics worth $9.28M as of Q3 2026.
  • Citigroup bought 2,041 Nurix Therapeutics shares in Q3 2026, an estimated $50.9K.
  • Nurix Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #1682 holding.
  • Citigroup first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 25 quarters since.
  • Citigroup's Nurix Therapeutics position peaked at $9.45M in Q2 2026.
  • 51 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.